Sage Journals: Discover world-class research

Abstract

Mepolizumab and reslizumab are anti-interleukin-5 monoclonal antibodies. Mepolizumab has been approved by the Food and Drug Administration (FDA) as add-on therapy for patients 12 years and older with severe asthma with an eosinophil phenotype. Reslizumab is currently under FDA review for approval also as add-on therapy in patients 12 years and older with moderate to severe asthma with an eosinophil phenotype. The differences between the products include route of administration (subcutaneous for mepolizumab and intravenous for reslizumab) and adverse effect risks. Adverse effects seen more commonly with mepolizumab than placebo included herpes zoster that may not be relevant to an adolescent patient but could be relevant for other viral infections. Anaphylaxis, elevations in creatine phosphokinase, and musculoskeletal events were seen in patients treated with reslizumab.

Get full access to this article

View all access options for this article.

References

Food and Drug Administration. Briefing Information for the June 11, 2015 Meeting of the Pulmonary Allergy Drugs Advisory Committee (Mepolizumab). 2015. www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ucm433815.htm (accessed January 14, 2016).

Food and Drug Administration. Briefing Information for the December 9, 2015 Meeting of the Pulmonary Allergy Drugs Advisory Committee (Reslizumab). 2015. www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ucm433815.htm (accessed January 14, 2016).

Chung

, Wenzel

, Brozek

, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014; 43:343–373.

National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, Publication No. 08–4051, 2007.

Global Initiative for Asthma (GINA). From the global strategy for asthma management and prevention. 2015. www.ginasthma.org/ (accessed April 17, 2015).

Wenzel

. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med, 2012; 18:716–725.

Miranda

, Busacker

, Balzar

, Trudeau

, Wenzel

. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol, 2004; 113:101–108.

Moore

, Fitzpatrick

, Li

, et al. Clinical heterogeneity in the severe asthma research program. Ann Am Thorac Soc, 2013; 10 Suppl:S118–S124.

Chung

. Managing severe asthma in adults: lessons from the ERS/ATS guidelines. Curr Opin Pulm Med, 2015; 21:8–15.

10.

Price

, Wilson

, Chisholm

, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy, 2016; 9:1–12.

11.

Food and Drug Administration.. Food and Drug Administration Approved Label for Mepolizumab (Nucala). 2015. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo (accessed January 14, 2016).

12.

Food and Drug Administration. Food and Drug Administration Summary Review for Mepolizumab. 2015. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo (accessed January 14, 2016).

Mepolizumab: A New Class of Treatment for Adolescents with Severe Persistent Asthma

Abstract

Get full access to this article

References